Comparing Inari Medical (NASDAQ:NARI) and Medigus (NASDAQ:MDGS)

Medigus (NASDAQ:MDGS – Get Rating) and Inari Medical (NASDAQ:NARI – Get Rating) are both business services companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Analyst Ratings

This is a summary of current ratings and price targets for Medigus and Inari Medical, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Medigus	0	0	0	0	N/A
Inari Medical	0	1	7	0	2.88

Inari Medical has a consensus target price of $89.11, suggesting a potential upside of 29.26%. Given Inari Medical’s higher possible upside, analysts plainly believe Inari Medical is more favorable than Medigus.

Profitability

This table compares Medigus and Inari Medical’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Medigus	N/A	N/A	N/A
Inari Medical	-6.87%	-6.78%	-5.72%

Institutional & Insider Ownership

9.2% of Medigus shares are held by institutional investors. Comparatively, 85.2% of Inari Medical shares are held by institutional investors. 2.2% of Medigus shares are held by insiders. Comparatively, 13.7% of Inari Medical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Valuation & Earnings

This table compares Medigus and Inari Medical’s gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Medigus	$91.86 million	0.06	-$9.81 million	N/A	N/A
Inari Medical	$383.47 million	10.28	-$29.27 million	($0.53)	-130.08

Medigus has higher earnings, but lower revenue than Inari Medical.

Risk & Volatility

Medigus has a beta of 0.08, meaning that its stock price is 92% less volatile than the S&P 500. Comparatively, Inari Medical has a beta of 1.12, meaning that its stock price is 12% more volatile than the S&P 500.

Summary

Inari Medical beats Medigus on 7 of the 11 factors compared between the two stocks.

About Medigus

(Get Rating)

Medigus Ltd., a technology-based company, provides medical-related devices and products in the United States, Europe, China, Israel, and internationally. It offers Medigus Ultrasonic Surgical Endostapler, an endoscopy system, which is used for the treatment of gastroesophageal reflux disease. The company also develops biological gels to protect patients against biological threats and reduce the intrusion of allergens and viruses through the upper airways and eye cavities. In addition, it develops, markets, and distributes software for internet users; and operates online stores for the sale of various consumer products on the Amazon online marketplace, as well as an online event management and ticketing platform. Further, the company develops, produces, and markets miniaturized imaging equipment, visualization solutions, and resistant cameras; electric vehicles; and wireless vehicle battery charging technologies. Medigus Ltd. was incorporated in 1999 and is headquartered in Tel Aviv-Yafo, Israel.

About Inari Medical

(Get Rating)

Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.